Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Surrozen Operating, Inc. is currently engaged in the patent prosecution process within the Biotechnology & Pharmaceuticals technology area. The data shows 4 pending office actions, reflecting an active effort to secure intellectual property in this complex field. This workload is distributed across 4 distinct examiners, suggesting that the company's innovations are being reviewed by a variety of technical specialists.
The prosecution is further divided among distinct art units. This level of distribution indicates that the company's research and development efforts touch upon several different technical or regulatory categories within the biotechnology sector. For practitioners, this requires a prosecution strategy that can adapt to the specific standards and historical tendencies of each of these art units.
YU, DELPHINUS DOU YI is the busiest examiner for this portfolio, currently overseeing 1 pending office action. With the pending matters spread across different examiners and art units, the outcome of each application will be highly dependent on the individual examiner's approach. Navigating this diverse prosecution environment requires careful attention to the specific requirements of each assigned art unit.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 2 (67%) |
| Double-patenting + other | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| YU, DELPHINUS DOU YI | 1 | 33.3% | +0.0% |
| ALLEN, MARIANNE P | 1 | 60.1% | +18.4% |
| LI, RUIXIANG | 1 | 59.5% | +18.7% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18397892 | FC-MODIFIED WNT SURROGATE MOLECULES AND USES THEREOF | ALLEN, MARIANNE P | — |
| 17438303 | MODULATION OF WNT SIGNALING IN GASTROINTESTINAL DISORDERS | LI, RUIXIANG | — |
| Art Unit | Apps |
|---|---|
| 1636 | 1 |
| 1647 | 1 |
| 1674 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18597679 | TISSUE-SPECIFIC WNT SIGNAL ENHANCING MOLECULES AND USES THEREOF | YU, DELPHINUS DOU YI | 1636 | §112 | Non-Final OA | — | Pending | Mar 06, 2024 |
| 18397892 | FC-MODIFIED WNT SURROGATE MOLECULES AND USES THEREOF | ALLEN, MARIANNE P | 1647 | §103§112DP | Non-Final OA | — | Pending | Dec 27, 2023 |
| 17438303 | MODULATION OF WNT SIGNALING IN GASTROINTESTINAL DISORDERS | LI, RUIXIANG | 1674 | §112 | Non-Final OA | — | Pending | Sep 10, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialSurrozen Operating, Inc. has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Delphinus Dou Yi Yu has the most, with 1 of Surrozen Operating, Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
